Cited by 1,626Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and TreatmentsLiver Diseases and Immunity

The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Open access

Ilyas, Sumera I., Khan, Shahid A., Hallemeier, Christopher L., Kelley, Robin K., Gores, Gregory J.·2018·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2017.157PMC PMC5819599

Open this paper in CoChat — free account

Abstract

Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management. The incidence of cholangiocarcinoma, particularly iCCA, has increased globally over the past few decades. Surgical resection remains the mainstay of potentially curative treatment for all three disease subtypes, whereas liver transplantation after neoadjuvant chemoradiation is restricted to a subset of patients with early stage pCCA. For patients with advanced-stage or unresectable disease, locoregional and systemic chemotherapeutics are the primary treatment options. Improvements in external-beam radiation therapy have facilitated the treatment of cholangiocarcinoma. Moreover, advances in comprehensive whole-exome and transcriptome sequencing have defined the genetic landscape of each cholangiocarcinoma subtype. Accordingly, promising molecular targets for precision medicine have been identified, and are being evaluated in clinical trials, including those exploring immunotherapy. Biomarker-driven trials, in which patients are stratified according to anatomical cholangiocarcinoma subtype and genetic aberrations, will be essential in the development of targeted therapies. Targeting the rich tumour stroma of cholangiocarcinoma in conjunction with targeted therapies might also be useful. Herein, we review the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2017.157

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J. W., Wasan, H. S., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T. J., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,423
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,157
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203

Flagged first, then by citations

Show all 175 references

Sorted by citations

Items 101–200 of 1,001

Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma
Supimon, K., Sangsuwannukul, T., Sujjitjoon, J., Phanthaphol, N., Chieochansin, T., Poungvarin, N., Wongkham, S., Junking, M., & Yenchitsomanus, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-85747-9 · Cited by 74
Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach
Urmán, J., Herranz, J. M., Uriarte, I., Rullán, M., Oyón, D., González, B., Fernández-Urién, I., Carrascosa, J., Bolado, F., Zabalza, L., et al. (2020) · Cancers · doi:10.3390/cancers12061644 · Cited by 71
Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges
Rizzo, A., Dadduzio, V., Lombardi, L., Ricci, A. D., & Gadaleta‐Caldarola, G. (2021) · Current Oncology · doi:10.3390/curroncol28050293 · Cited by 70
Biology of IDH mutant cholangiocarcinoma
Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 71
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khoueiry, A. B., Hockenberry, A. J., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00510 · Cited by 71
Self-citation
Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma
Dondossola, D. E., Ghidini, M., Grossi, F., Rossi, G. E., & Foschi, D. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i25.3542 · Cited by 69
Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma
Pant, K., Peixoto, E., Richard, S., & Gradilone, S. A. (2020) · Cells · doi:10.3390/cells9030780 · Cited by 69
YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation
Huang, C., Zhu, Y., Xu, Q., Chen, S., Huang, Y., Zhao, G., Ni, X., Liu, B., Zhao, W., & Yin, X. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.848 · Cited by 68
Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link
Chen, C., Nelson, L. J., Avila, M. A., & Cubero, F. J. (2019) · Cells · doi:10.3390/cells8101172 · Cited by 68
Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation
Shu, L., Li, X., Liu, Z., Li, K., Shi, A., Tang, Y., Zhao, L., Huang, L., Zhang, Z., Zhang, D., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000437 · Cited by 67
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis
Mancarella, S., Serino, G., Dituri, F., Cigliano, A., Ribback, S., Wang, J., Chen, X., Calvisi, D. F., & Giannelli, G. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0505-4 · Cited by 67
Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis
Goeppert, B. F., Stichel, D., Tóth, R., Fritzsche, S., Loeffler, M., Schlitter, A. M., Neumann, O., Assenov, Y., Vogel, M. N., Mehrabi, A., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-322983 · Cited by 64
The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics
Islam, M. T., Chen, F., & Chen, H. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108811 · Cited by 65
HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc
Li, Z., Liu, J., Chen, T., Sun, R., Liu, Z., Qiu, B., Xu, Y., & Zhang, Z. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01890-1 · Cited by 64
Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part I: Classification, diagnosis and staging
Alvaro, D., Hassan, C., Cardinale, V., Carpino, G., Fabris, L., Gringeri, E., Granata, V., Mutignani, M., Morement, H., Giuliante, F., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.06.045 · Cited by 65
The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway
Ma, W., Han, C., Zhang, J., Song, K., Chen, W., Kwon, H., & Wu, T. (2020) · Hepatology · doi:10.1002/hep.31141 · Cited by 62
A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma
Zhang, T., Zhang, S., Chen, J., Lin, Z., Deng, T., Xie, X., Deng, L., Li, X., Ma, J., Ding, X., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.751795 · Cited by 62
Immunobiology of cholangiocarcinoma
Tomlinson, J. L., Valle, J. W., & Ilyas, S. I. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.010 · Cited by 62
Self-citation
Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma
Colyn, L., Bárcena‐Varela, M., Álvarez‐Sola, G., Latasa, M. U., Uriarte, I., Santamaría, E., Herranz, J. M., Santos‐Laso, Á., Arechederra, M., de Gauna, M. R., et al. (2020) · Hepatology · doi:10.1002/hep.31642 · Cited by 62
Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results
Xu, C., Li, L., Xu, W. L., Du, C., Yang, L., Tong, J., & Yi, Y. (2019) · International Journal of Hyperthermia · doi:10.1080/02656736.2019.1571247 · Cited by 61
Patient-Derived Organoids of Cholangiocarcinoma
Maier, C., Zhu, L., Nanduri, L. K., Kühn, D., Kochall, S., Thepkaysone, M.-L., William, D., Grützmann, K., Klink, B., Betge, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168675 · Cited by 60
Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma
Ilyas, S. I., Eaton, J. E., Yang, J. D., Chandrasekhara, V., & Gores, G. J. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1655775 · Cited by 60
Self-citation
Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a Propensity Score-Matched Study
Kim, S. H., Han, D. H., Choi, G. H., Choi, J. S., & Kim, K. S. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3899-2 · Cited by 60
Identification of a Pan‐Gamma‐Secretase Inhibitor Response Signature for Notch‐Driven Cholangiocarcinoma
O’Rourke, C. J., Matter, M. S., Nepal, C., Oliveira, R. C., Ton, P. T., Factor, V. M., & Andersen, J. B. (2019) · Hepatology · doi:10.1002/hep.30816 · Cited by 57
METTL3 protects METTL14 from STUB1‐mediated degradation to maintain m6A homeostasis
Zeng, Z., Pan, Q., Sun, Y., Huang, H., Chen, X., Chen, T., He, B., Ye, H., Zhu, S.-X., Pu, K., et al. (2023) · EMBO Reports · doi:10.15252/embr.202255762 · Cited by 61
New insights into the pathophysiology and clinical care of rare primary liver cancers
Gigante, E., Paradis, V., Ronot, M., Cauchy, F., Soubrane, O., Ganne‐Carrié, N., & Nault, J. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100174 · Cited by 58
Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
Maruki, Y., Morizane, C., Arai, Y., Ikeda, M., Ueno, M., Ioka, T., Naganuma, A., Furukawa, M., Mizuno, N., Uwagawa, T., et al. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01735-2 · Cited by 58
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
Li, Z., Zhou, H., Xia, Z., Xia, T., Du, G., Franziska, S. D., Li, X., Zhai, X., & Jin, B. (2023) · Biomarker Research · doi:10.1186/s40364-023-00473-w · Cited by 59
Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma
Vilà, P. C., Ravichandra, A., Lizaso, A. A., Perugorria, M. J., & Affò, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000206 · Cited by 62
BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways
Chen, X., Yin, Y., Cheng, J., Huang, A., Hu, B., Zhang, X., Sun, Y., Wang, J., Wang, Y., Ji, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1087-7 · Cited by 57
Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression
Sirica, A. E., Strazzabosco, M., & Cadamuro, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.005 · Cited by 59
Role of MicroRNA-30c in cancer progression
Han, W., Cui, H., Liang, J., & Su, X. (2020) · Journal of Cancer · doi:10.7150/jca.38449 · Cited by 56
Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study
Zhang, Z., Zhou, Y., Hu, K., Wang, D., Wang, Z., & Huang, Y. (2020) · BMC Cancer · doi:10.1186/s12885-020-06781-w · Cited by 56
Systemic treatment of advanced or recurrent biliary tract cancer
Zhang, W., Zhou, H., Wang, Y., Zhang, Z., Cao, G., Song, T., Zhang, T., & Li, Q. (2020) · BioScience Trends · doi:10.5582/bst.2020.03240 · Cited by 56
Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
Rompianesi, G., Martino, M. D., Gordon-Weeks, A. N., Montalti, R., & TROISI, R. I. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i5.332 · Cited by 56
Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma
Huang, F., Liu, Z., Song, Y., Wang, G., Shi, A., Chen, T., Huang, S., Lian, S., Li, K., Tang, Y., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.017 · Cited by 58
Noncoding RNA in Cholangiocarcinoma
Salati, M., & Braconi, C. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1676097 · Cited by 56
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Goyal, L., Sirard, C. A., Schrag, M. L., Kagey, M. H., Eads, J. R., Stein, S., El-Khoueiry, A. B., Manji, G. A., Abrams, T. A., Khorana, A. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1310 · Cited by 55
Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinoma
Yu, Y., Zhang, M., Wang, N., Li, Q., Yang, J., Yan, S., He, X., Ji, G., & Miao, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0768-6 · Cited by 54
Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications
Wang, M., Gu, J., Zhang, X., Yang, J.-P., Zhang, X., & Fang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.753706 · Cited by 56
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine
Rimassa, L., Personeni, N., Aghemo, A., & Lleò, A. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.03.007 · Cited by 54
Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation
Rodríguez‐Perálvarez, M., Gómez‐Bravo, M. Á., Sánchez‐Antolín, G., de la Rosa, G., Bilbao, I., & Colmenero, J. (2020) · Transplantation · doi:10.1097/tp.0000000000003281 · Cited by 54
Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part II: Treatment
Alvaro, D., Hassan, C., Cardinale, V., Carpino, G., Fabris, L., Gringeri, E., Granata, V., Mutignani, M., Morement, H., Giuliante, F., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.08.030 · Cited by 54
Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma
Lomphithak, T., Akara-amornthum, P., Murakami, K., Hashimoto, M., Usubuchi, H., Iwabuchi, E., Unno, M., Cai, Z., Sasano, H., & Jitkaew, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-89977-9 · Cited by 53
Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities
Wang, X., Zhu, W., Wang, Z., Huang, J.-B., Wang, S., Bai, F., Li, T., Zhu, Y., Zhao, J., Yang, X., et al. (2021) · Theranostics · doi:10.7150/thno.63417 · Cited by 56
The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy
Zaki, M. B., Abulsoud, A. I., Elshaer, S. S., Fathi, D., Abdelmaksoud, N. M., El‐Mahdy, H. A., Ismail, A., Elsakka, E. G. E., Sallam, A.-A. M., & Doghish, A. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154437 · Cited by 53
Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure
Carpino, G., Overi, D., Melandro, F., Grimaldi, A., Cardinale, V., Matteo, S. D., Mennini, G., Rossi, M., Alvaro, D., Barnaba, V., et al. (2019) · Clinical Proteomics · doi:10.1186/s12014-019-9257-x · Cited by 55
Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile
Vedeld, H. M., Grimsrud, M. M., Andresen, K., Pharo, H. D., von Seth, E., Karlsen, T. H., Honne, H., Paulsen, V., Färkkilä, M. A., Bergquist, A. M., et al. (2021) · Hepatology · doi:10.1002/hep.32125 · Cited by 53
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins
Qiao, Y., Chen, J., Wang, X., Yan, S., Tan, J., Xia, B., Chen, Y., Lin, K., Zou, F., Liu, B., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12452 · Cited by 55
Piezo 1 activation facilitates cholangiocarcinoma metastasis via Hippo/YAP signaling axis
Zhu, B., Qian, W., Han, C., Bai, T., & Hou, X. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.02.026 · Cited by 56
Cholangiocarcinoma: a review of the literature and future directions in therapy
Halder, R., Amaraneni, A., & Shroff, R. T. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-20-396 · Cited by 52
CRISPR-Cas14a-integrated strand displacement amplification for rapid and isothermal detection of cholangiocarcinoma associated circulating microRNAs
Chi, Z., Wu, Y., Chen, L., Yang, H., Khan, M. R., Busquets, R., Huang, N., Lin, X., Deng, R., Yang, W., et al. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339763 · Cited by 50
Application of photodynamic therapy for liver malignancies
Zou, H., Wang, F., Zhou, J., Liu, X., He, Q., Wang, C., Zheng, Y., Wen, Y., & Xiong, L. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2020.02.10 · Cited by 50
LncRNA TTN-AS1 promotes the progression of cholangiocarcinoma via the miR-320a/neuropilin-1 axis
Zhu, H., Zhai, B., He, C., Li, Z., Gao, H., Niu, Z., Jiang, X. L., Lü, J., & Sun, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02896-x · Cited by 50
Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles
Beal, E. W., Cloyd, J. M., & Pawlik, T. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010104 · Cited by 50
Classifications and misclassification in cholangiocarcinoma
Cardinale, V. (2019) · Liver International · doi:10.1111/liv.13998 · Cited by 50
Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression
Qian, M., Yan, F., Wang, W., Du, J., Yuan, T., Wu, R., Zhao, C., Wang, J., Lu, J., Zhang, B., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.003 · Cited by 48
Synthesis of Monodisperse ZIF-67@CuSe@PVP Nanoparticles for pH-Responsive Drug Release and Photothermal Therapy
Wu, J., Zhang, Z., Qiao, C., Yi, C., Xu, Z., Chen, T., & Dai, X. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01124 · Cited by 49
Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway
Liu, Z., Liu, J., Chen, T., Wang, Y., Shi, A., Li, K., Li, X., Qiu, B., Zheng, L., Zhao, L., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02313-x · Cited by 49
METTL5-mediated 18S rRNA m6A modification promotes oncogenic mRNA translation and intrahepatic cholangiocarcinoma progression
Dai, Z., Zhu, W., Hou, Y., Zhang, X., Ren, X., Lei, K., Liao, J., Liu, H., Chen, Z., Peng, S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.014 · Cited by 48
Exosomal circRNAs: new players in the field of cholangiocarcinoma
Louis, C., Desoteux, M., & Coulouarn, C. (2019) · Clinical Science · doi:10.1042/cs20190940 · Cited by 48
The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
Wang, D., Yang, X., Long, J., Lin, J., Mao, J., Xie, F., Wang, Y., Wang, Y., Xun, Z., Bai, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646979 · Cited by 48
Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine
Malenica, I., Donadon, M., & Lleò, A. (2020) · Cancers · doi:10.3390/cancers12082190 · Cited by 48
Radiomics using CT images for preoperative prediction of futile resection in intrahepatic cholangiocarcinoma
Chu, H., Liu, Z., Liang, W., Zhou, Q., Zhang, Y., Lei, K., Tang, M., Cao, Y.-H., Chen, S., Peng, S., et al. (2020) · European Radiology · doi:10.1007/s00330-020-07250-5 · Cited by 47
Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy
Gao, J., Fang, Y., Chen, J., Tang, Z., Tian, M., Jiang, X., Tao, C., Huang, R., Zhu, G., Qu, W., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02760-0 · Cited by 46
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Martin, E. D., Fulgenzi, C. A. M., Celsa, C., Laurent-Bellue, A., Torkpour, A., Lombardi, P., D’Alessio, A., & Pinato, D. J. (2024) · Gut · doi:10.1136/gutjnl-2024-332125 · Cited by 51
Immune Therapy for Liver Cancers
Hilmi, M., Vienot, A., Rousseau, B., & Neuzillet, C. (2019) · Cancers · doi:10.3390/cancers12010077 · Cited by 46
GATA6 promotes epithelial-mesenchymal transition and metastasis through MUC1/β-catenin pathway in cholangiocarcinoma
Deng, X., Jiang, P., Chen, J., Li, J., Li, D., He, Y., Jiang, Y., Zhang, Y., Xu, S., Li, X., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03070-z · Cited by 46
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin
Martin, R. C. G., Simo, K. A., Hansen, P., Rocha, F. G., Philips, P., McMasters, K. M., Tatum, C. M., Kelly, L. R., Driscoll, M., Sharma, V. R., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11932-3 · Cited by 45
Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies
Yu, X., Zhu, L., Wang, T., & Chen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1037945 · Cited by 45
New epidemiologic trends in cholangiocarcinoma
Pascale, A., Rosmorduc, O., & Duclos‐Vallée, J. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102223 · Cited by 47
LncRNA HEIH promotes cell proliferation, migration and invasion in cholangiocarcinoma by modulating miR-98-5p/HECTD4
Wan, T., Wang, H., Gou, M., Si, H., Wang, Z., Yan, H., Liu, T., Chen, S., Fan, R., Qian, N., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109916 · Cited by 45
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
Personeni, N., Lleò, A., Pressiani, T., Colapietro, F., Openshaw, M. R., Stavraka, C., Pouptsis, A., Pinato, D. J., & Rimassa, L. (2020) · Cancers · doi:10.3390/cancers12113370 · Cited by 45
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Gómez‐España, M. A., Montés, A. F., García‐Carbonero, R., Macarulla, T. M., Maurel, J., Martín, Á., Pazo-Cid, R., Vera, R., Carrato, A., & Feliú, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02573-1 · Cited by 45
Natural Killer–Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy
Cazzetta, V., Franzese, S., Carenza, C., Bella, S. D., Mikulak, J., & Mavilio, D. (2021) · Cancers · doi:10.3390/cancers13092184 · Cited by 47
Computational Recognition and Clinical Verification of TGF-β-Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma
Liu, Z., Weng, S., Xu, H., Wang, L., Liu, L., Zhang, Y., Guo, C., Dang, Q., Xing, Z., Lu, T., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757919 · Cited by 44
Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis
Keenan, B. P., McCarthy, E. E., Ilano, A., Yang, H., Zhang, L., Allaire, K. M., Fan, Z., Li, T. Y., Lee, D. S., Sun, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111384 · Cited by 46
Self-citation
Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection
Qu, W., Zhou, P., Liu, W., Tian, M., Jin, L., Jiang, X., Wang, H., Tao, C.-Y., Fang, Y., Zhou, Y., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.23 · Cited by 44
The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma
Liu, J., Ren, G., Li, K., Liu, Z., Wang, Y., Chen, T., Mu, W., Yang, X., Li, X., Shi, A., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00897-7 · Cited by 43
Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression
Wang, Y., Li, K., Zhao, W., Liu, Z., Liu, J., Shi, A., Chen, T., Mu, W., Xu, Y., Pan, C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04451-8 · Cited by 44
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Khan, S. A., Genus, T., Morement, H., Murphy, A., Rous, B., & Tataru, D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.024 · Cited by 44
Self-citation
Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study
Kang, M. J., Lim, J., Han, S., Park, H. M., Kim, S., Lee, W. J., Woo, S. M., Kim, T. H., Won, Y., & Park, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13605-3 · Cited by 43
Circular RNAs in cholangiocarcinoma
Liao, W., Feng, Q., Liu, H., Du, J., Chen, X., & Zeng, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215980 · Cited by 44
Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein
Saikawa, S., Kaji, K., Nishimura, N., Seki, K., Sato, S., Nakanishi, K., Kitagawa, K., Kawaratani, H., Kitade, M., Moriya, K., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.021 · Cited by 43
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations
Neuzillet, C., Gardini, A. C., Brieau, B., Vivaldi, C., Smolenschi, C., Brandi, G., Tougeron, D., Filippi, R., Vienot, A., Silvestris, N., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.019 · Cited by 43
CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
Huang, T., Ding, X., Xu, G., Chen, G., Cao, Y. Q., Peng, C., Shen, S., Lv, Y., Wang, L., & Zou, X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1831-7 · Cited by 43
THE ROLE OF MINIMALLY INVASIVE HEPATECTOMY FOR HILAR AND INTRAHEPATIC CHOLANGIOCARCINOMA: A SYSTEMATIC REVIEW OF THE LITERATURE
Shiraiwa, D. K., de Carvalho, P. F. D. C., Maeda, C. T., Silva, L. C., Forones, N. M., Filho, G. D. J. L., Linhares, M. M., & Araújo, R. L. C. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25821 · Cited by 44
Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma
Pant, K., Richard, S., Peixoto, E., & Gradilone, S. A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00113 · Cited by 45
Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma
Guedj, N., Blaise, L., Cauchy, F., Albuquerque, M., Soubrane, O., & Paradis, V. (2020) · Modern Pathology · doi:10.1038/s41379-020-00656-y · Cited by 43
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma
Monge, C., Pehrsson, E. C., Xie, C., Duffy, A. G., Mabry, D., Wood, B. J., Kleiner, D. E., Steinberg, S. M., Figg, W. D., Redd, B. A., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab073 · Cited by 43
Pathology of Cholangiocarcinomas
Guedj, N. (2022) · Current Oncology · doi:10.3390/curroncol30010030 · Cited by 42
Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma
Angenard, G., Merdrignac, A., Louis, C., Edeline, J., & Coulouarn, C. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.03.019 · Cited by 42
Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers
Zhang, W., Shi, J., Wang, Y., Zhou, H., Zhang, Z., Han, Z., Li, G., Yang, B., Cao, G., Ke, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02745-y · Cited by 42
Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity
Zheng, H., Zheng, W., Wang, Z., Tao, Y., Huang, Z., Yang, L., Ouyang, L., Duan, Z., Zhang, Y.-N., Chen, B.-N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845193 · Cited by 42
ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway
Chen, J., Tang, Y., Qin, D., Yu, X., Tong, H., Tang, C., & Tang, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04804-1 · Cited by 40
Long Non-Coding RNA PCAT6 Induces M2 Polarization of Macrophages in Cholangiocarcinoma via Modulating miR-326 and RhoA-ROCK Signaling Pathway
Tu, J., Wu, F., Chen, L., Zheng, L., Yang, Y., Ying, X., Song, J., Chen, C., Hu, X., Zhao, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.605877 · Cited by 41
Combination of albumin-globulin score and skeletal muscle index predicts long-term outcomes of intrahepatic cholangiocarcinoma patients after curative resection
Li, H., Dai, J., Lan, T., Liu, H., Wang, J., Cai, B., Xu, L., Yuan, K., Wang, G., & Wu, H. M. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.04.038 · Cited by 41
Surgical management of intrahepatic cholangiocarcinoma
Hewitt, D. B., Brown, Z. J., & Pawlik, T. M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.1999809 · Cited by 41
3D Bioprinting: An Important Tool for Tumor Microenvironment Research
Li, Y., Liu, J., Xu, S. Q., & Wang, J. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s435845 · Cited by 40
LncRNA HOTAIR suppresses cell apoptosis, autophagy and induces cell proliferation in cholangiocarcinoma by modulating the miR-204-5p/HMGB1 axis
Lu, M., Qin, X., Zhou, Y., Li, G., Liu, Z., Yue, H., & Geng, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110566 · Cited by 40

Authors: Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J.
Affiliations: Mayo Clinic (US)
Hammersmith Hospital (GB)
University of California San Francisco Medical Center (US)
Corresponding author: Gores, Gregory J.
ORCID: Ilyas, Sumera I.
Khan, Shahid A.
Hallemeier, Christopher L.
Kelley, Robin K.
Gores, Gregory J.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2017-10-10
Volume: 15
Issue: 2
Pages: 95-111
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2017.157
PMC: PMC5819599
OpenAlex: W2763492611
Cited by: 1,626
References: 175
Citations by year: 2026: 88 · 2025: 164 · 2024: 252 · 2023: 247 · 2022: 253 · 2021: 272 · 2020: 209 · 2019: 82 · 2018: 51 · 2017: 1
FWCI: 19.88
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: Cholangiocarcinoma Foundation
National Institutes of Health
Institute of Chemistry, Chinese Academy of Sciences
National Cancer Institute (R03CA212877)
National Institute of Diabetes and Digestive and Kidney Diseases (R56DK059427, R01DK059427, P30DK084567)
Topics: Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: cholangiocarcinoma, intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, distal cholangiocarcinoma, pathogenesis, surgical resection, liver transplantation, neoadjuvant chemoradiotherapy, locoregional chemotherapy, external beam radiotherapy, genetic landscape, molecular targets, precision medicine, immunotherapy, tumor stroma, biomarkers
MeSH terms: Adult, Cell Differentiation, Humans, Liver Neoplasms, Prognosis, Liver Transplantation, Cholangiocarcinoma, Neoadjuvant Therapy, Precision Medicine, Molecular Targeted Therapy, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks